SIRPA and myeloid sarcoma: Although no significant prognostic distinctions were observed between patients with SIRPα-positive neoplastic cells (nSIRPα) and those exhibiting SIRPα expression on non-neoplastic stromal cells in the TME (miSIRPα), individuals with CD47-positive myeloid sarcoma experienced notably prolonged OS compared to their counterparts with CD47-negative myeloid sarcoma (Tanaka et al. 2024).